In the absence of a submission from the holder of the marketing authorisation, propranolol (Hemangiol®) cannot be endorsed for use within NHS Wales for the treatment of proliferating infantile haemangioma requiring systemic therapy: life- or function-threatening haemangioma; ulcerated haemangioma with pain and/or lack of response to simple wound care measures; or haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months. This product is currently not marketed in the UK.